Integrating Network Pharmacology and In Vitro 3D Cardiac Organoid Model Validation to Investigate the Action Mechanism of Shenfu Xiangshao Decoction on Heart Failure [0.03%]
基于网络药理学和体外心脏类器官模型验证的参附香肖饮治疗心衰作用机制研究
Sijie Yao,Hui Zhang,Min Li et al.
Sijie Yao et al.
Heart failure (HF) represents a significant global public health challenge with profound implications for human health. Shenfu Xiangshao Decoction (SFXSD) is a commonly utilized adjuvant therapy for HF. However, its molecular mechanism rema...
Safety and effectiveness of somatostatin and analogues on chest tube output after coronary artery bypass grafting: A scoping review [0.03%]
生长抑素及其类似物减少冠状动脉旁路移植术后胸管引流的疗效和安全性：系统综述
Caitlin M Gibson,Alisa K Escaño,Katherine D Hobe et al.
Caitlin M Gibson et al.
Somatostatin and analogues may reduce chest tube (CT) output in chylothorax caused by post-coronary artery bypass grafting (CABG). However, data is limited to case reports and series. This scoping review aimed to describe the efficacy and s...
When Phenotyping Is the Intervention: Personlized Treatment of Diffuse Coronary Artery Disease [0.03%]
当表型分析即是干预措施时——弥漫性冠状动脉疾病个性化治疗的策略与展望
Salvatore Giordano,Alberto Morello,Giuseppe Biondi-Zoccai et al.
Salvatore Giordano et al.
Closing the translational gap in cardiovascular artificial intelligence: from drug discovery to evidence synthesis [0.03%]
心血管人工智能的转化差距及如何从药物发现到证据综合予以弥补
Giuseppe Biondi-Zoccai,Giacomo Frati,George W Booz
Giuseppe Biondi-Zoccai
Role of the Gut Microbiome in Modulating Interactions Between β-Lactam Antibiotics and Statins in Coronary Heart Disease [0.03%]
肠道微生物组在调节β-内酰胺类抗生素和他汀类药物在冠心病中相互作用中的作用
Guohui Wang,Yan Luo,Sangcang Song et al.
Guohui Wang et al.
Clinical evidence suggests that the lipid-lowering efficacy of statins may be diminished by concurrent β-lactam administration in patients with coronary heart disease (CHD), yet the mechanisms driving this potential drug-drug interaction, ...
Alanna Arroues,Michael Longo,Mariko Harper
Alanna Arroues
Hypertrophic Cardiomyopathy (HCM) is the most commonly inherited cardiomyopathy worldwide, characterized by left ventricular hypertrophy and hypercontractility. Many cases of HCM are due to pathogenic changes in cardiac sarcomere proteins. ...
Cannabidiol Protects the Heart from Ischemia-Reperfusion Injury Through SIRT-1/PGC-1α Activation and NF-κB Modulation: Experimental Insights [0.03%]
大麻二酚通过SIRT-1/PGC-1α激活和NF-κB调节保护心脏免受缺血再灌注损伤：实验见解
Fatih Aksoy,Mehtap Savran,Dincer Uysal et al.
Fatih Aksoy et al.
Myocardial ischemia-reperfusion (I/R) injury remains a major cause of acute cardiac dysfunction and is characterized by oxidative stress, inflammation, and apoptosis. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, has been reported...
Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives [0.03%]
PCSK9抑制剂治疗Lp(a)相关动脉粥样硬化的疗效：证据与展望
Xinyan Li,Zhongsu Wang,Juan Liang et al.
Xinyan Li et al.
Lipoprotein(a) [Lp(a)] is a genetically determined independent risk factor for atherosclerotic cardiovascular disease (ASCVD) that drives a significant residual risk through pro-atherogenic, pro-inflammatory, and prothrombotic pathways. How...
The comparative effects of S-amlodipine versus racemic amlodipine on long-term cardiovascular outcomes in subjects with hypertension: a nationwide population-based cohort study [0.03%]
塞氨氯地平与外消旋氨氯地平对高血压患者长期心血管预后影响的队列研究
Hack-Lyoung Kim,Bora Lee,Soojin Im
Hack-Lyoung Kim
Although S-amlodipine is known to have similar effects in lowering blood pressure and fewer side effects compared to amlodipine (= mixture of S- and R-amlodipine), there are no available data on its impact on long-term cardiovascular progno...
Pharmacokinetic Modeling of Ticagrelor and Ticagrelor Active Metabolite Removal by the DrugSorb-ATR Device in a Randomized Controlled Study of Patients Undergoing Cardiac Surgery [0.03%]
替卡格雷及其活性代谢产物通过DrugSorb-ATR装置清除的药代动力学模型：一项心脏手术患者随机对照研究
Diane R Mould,Kevin R Sweeney,Jayne Prats et al.
Diane R Mould et al.
Excessive surgical bleeding is a potential risk in patients taking ticagrelor who must undergo urgent cardiothoracic (CT) surgery before adequate washout of the drug can occur. The DrugSorb-Antithrombotic removal (ATR) device is a polymer s...
Randomized Controlled Trial
Journal of cardiovascular pharmacology. 2026 Feb 1;87(2):105-113. DOI:10.1097/FJC.0000000000001779 2026